shutterstock_1953872293_marlon_trottmann

Marlon Trottmann / Shutterstock.com

13 December 2022AmericasStaff Writer

Amgen seals $28m deal for biotech

Two rivals withdrew from acquisition process | Agreement provides access to blockbuster medicines | Janssen Global Services | Sanofi.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Amgen continues M&A flurry with $3.7bn deal

8 August 2022 Pharma company to acquire biopharma focused on autoimmune, inflammatory and cancer therapeutics / Deal includes acquisition of Tavneos / Spate of acquisitions follows increased competition.

FTC sues to bar Amgen from major IP $28bn acquisition

18 May 2023 The $27.8 billion acquisition would allegedly enable the pharma giant to stifle competition for thyroid eye disease and chronic refractory gout treatments | There is currently no market competition for the treatments.

More on this story

Amgen continues M&A flurry with $3.7bn deal

8 August 2022 Pharma company to acquire biopharma focused on autoimmune, inflammatory and cancer therapeutics / Deal includes acquisition of Tavneos / Spate of acquisitions follows increased competition.

FTC sues to bar Amgen from major IP $28bn acquisition

18 May 2023 The $27.8 billion acquisition would allegedly enable the pharma giant to stifle competition for thyroid eye disease and chronic refractory gout treatments | There is currently no market competition for the treatments.

More on this story

Amgen continues M&A flurry with $3.7bn deal

8 August 2022 Pharma company to acquire biopharma focused on autoimmune, inflammatory and cancer therapeutics / Deal includes acquisition of Tavneos / Spate of acquisitions follows increased competition.

FTC sues to bar Amgen from major IP $28bn acquisition

18 May 2023 The $27.8 billion acquisition would allegedly enable the pharma giant to stifle competition for thyroid eye disease and chronic refractory gout treatments | There is currently no market competition for the treatments.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB

Attorney v examiner: Navigating patenting's AI tools ‘arms race’

Lewis Roca promotes tech expert to managing partner

Panitch Schwarze brings in molecular biologist

US targets ‘product hopping’ with biologic litigation curbs

UPC confirms validity of Edwards Lifesciences heart valve tech patent

ITC concludes row over biotech lab equipment between US and German rivals

UKIPO launches ‘revolutionary’ patent filing and AI tool